Reading SGMO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGMO free→Reading SGMO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGMO free→Health CareSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it is priced below typical for sector peers. Peer multiples imply a price about 20% above where it trades (it looks cheap on this basis); the read is fair, but weakening. If SGMO cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.15 SGMO trades at 1× p/s, below its 2× p/s peer median. Our $0.33 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 55% below a flat-multiple fair value, in line with our forecast of about -60%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.73x of net income into operating cash flow.
Not enough signal yet.
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Not enough price history for this read.
How much price usually moves either way.
Not enough price history for this read.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,293.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SGMO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 14, 2026, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care (broad).
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SGMO Sangamo Therapeutics Inc | Below typical Show detailsSector percentile: 14 of 100 | fair | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
UNH UnitedHealth Group | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to reduce non-GAAP operating expenses to between $100 million and $120 million in 2026.
Stated in 3 of last 3 quarters. Operating expenses guidance reduced from $125M-$145M in 2025 to $100M-$120M in 2026. Despite the guidance reduction, the financials show a net income loss of $30.99M in 2026-Q1, indicating limited progress towards profitability.
“We expect non-GAAP total operating expenses in the range of approximately $100 million to $120 million in 2026.”
“We expect non-GAAP total operating expenses in the range of approximately $110 million to $120 million in 2026.”
“We continue to expect non-GAAP total operating expenses in the range of approximately $125 million to $145 million in 2025.”
Management is focused on increasing revenue, as evidenced by their ongoing efforts.
Stated in 3 of last 3 quarters. Revenue decreased from $14.23M in 2025-Q4 to $1.44M in 2026-Q1, indicating a decline despite management's focus on growth. The trajectory shows limited progress in achieving revenue growth.
Results of Operations and Financial Condition. On March 30, 2026, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2, 2026, the employment of Prathyusha Duraibabu, the Company’s principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Sangamo’s Vice President, Finance and Corporate Controller and principal accounting officer, has been appointed to the position of Interim Chief Financial Officer and will serve as the Company’…
Entry into a Material Definitive Agreement. Underwritten Offering On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 35,190,292 shares of the Company’s common stock, par value $0.01 per sh…
is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the C…
“Revenue for the quarter was $1.44 million, reflecting ongoing efforts to grow.”
“Revenue for the quarter was $14.23 million, indicating growth focus.”
“Revenue for the quarter was $0.58 million, showing growth efforts.”